There are 2867 resources available
1188TiP - ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
Presenter: Joop De Langen
Session: Poster session 16
1189TiP - Phase II study of anti-TIGIT GSK4428859A (GSK’859A)/EOS-448 + anti-CD96 GSK6097608 (GSK’608) + anti-PD-1 dostarlimab in non-small cell lung cancer (NSCLC)
Presenter: David Spigel
Session: Poster session 16
1190TiP - Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Presenter: Helena A. Yu
Session: Poster session 16
1191TiP - Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)
Presenter: Lucy Corke
Session: Poster session 16
1192TiP - GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial
Presenter: Francois Ghiringhelli
Session: Poster session 16
1193TiP - A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC
Presenter: Tudor-Eliade Ciuleanu
Session: Poster session 16
1197TiP - A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation
Presenter: Dae Ho Lee
Session: Poster session 16